# Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Study · id `cardio:ct-nct07116928` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07116928](<https://clinicaltrials.gov/study/NCT07116928>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07116928

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1244 participants.

## Technical summary

Registry record NCT07116928. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-30 (anticipated); primary completion 2031-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1244 participants (planned count; ClinicalTrials.gov record NCT07116928, source copy `cardio:ctgov-nct07116928-2025-11-18`, retrieved 2026-10-26)
- Planned start: 2025-11-30 (anticipated) (ClinicalTrials.gov record NCT07116928, source copy `cardio:ctgov-nct07116928-2025-11-18`, retrieved 2026-10-26)
- Primary completion: 2031-10-30 (anticipated) (ClinicalTrials.gov record NCT07116928, source copy `cardio:ctgov-nct07116928-2025-11-18`, retrieved 2026-10-26)
- Completion: 2031-12-30 (anticipated) (ClinicalTrials.gov record NCT07116928, source copy `cardio:ctgov-nct07116928-2025-11-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07116928, source copy `cardio:ctgov-nct07116928-2025-11-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07116928-2025-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- Acronym: GLOW-CKD
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Condition: CKD - Chronic Kidney Disease
- Intervention (Drug): ganagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (`cardio:org-hangzhou-zhongmei-huadong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 6846cbe440dac403dcc508c02b0653cf729ef93c90a5202d01b9437e28640c16
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
